Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts.

ABSTRACT:

SUBMITTER:

PROVIDER: S-EPMC8981597 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts.

Journal of translational medicine 20220405 Suppl 1

PMID: 35379244

Similar Datasets

Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts.

Project description: Not available

| S-EPMC7989079 | biostudies-literature

Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts.

Project description: Not available

| S-EPMC7011210 | biostudies-literature

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Project description: Not available

| S-EPMC6334383 | biostudies-literature

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.

Project description:Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies.The virtual Immunotherapy Bridge (December 1st-2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.

| S-EPMC9172186 | biostudies-literature

2021 ASN Virtual Meeting Abstracts.

Project description: Not available

| S-EPMC8514745 | biostudies-literature

2021 ASCB Annual Meeting abstracts.

Project description: Not available

| S-EPMC8694078 | biostudies-literature

2021 Diabetes Technology Meeting Abstracts

Project description: Not available

| S-EPMC8861775 | biostudies-literature

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.

Project description:After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Leveraging the neoadjuvant treatment setting offers the ability to deeply interrogate longitudinal tissue in order to gain translatable, pan-malignancy insights into response and mechanisms of resistance to immunotherapy. Neoadjuvant immunotherapy across cancers was a focus of discussion at the virtual Immunotherapy Bridge meeting (December 1-2, 2021). Clinical, biomarker, and pathologic insights from prostate, breast, colon, and non-small-cell lung cancers, melanoma and non-melanoma skin cancers were discussed and are summarized in this report.

| S-EPMC9199148 | biostudies-literature

30th Annual Computational Neuroscience Meeting: CNS*2021-Meeting Abstracts.

Project description: Not available

| S-EPMC8687879 | biostudies-literature

Abstracts for the 2021 TSANZ Annual Scientific Meeting

Project description: Not available

| S-EPMC8109145 | biostudies-literature